Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

BackgroundFirst-line treatment with nivolumab plus ipilimumab (N+I) or nivolumab plus ipilimumab with two cycles of chemotherapy (N+I+chemotherapy) improve overall survival and progression-free survival for patients with metastatic non-small cell lung cancer (NSCLC), yet researchers have not concomi...

Full description

Bibliographic Details
Main Authors:	Szu-Chun Yang, Natalia Kunst, Cary P. Gross, Jung-Der Wang, Wu-Chou Su, Shi-Yi Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-12-01
Series:	Frontiers in Oncology
Subjects:	cost-effectiveness immunotherapy non-small cell lung cancer nivolumab ipilimumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.760686/full

Similar Items

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020-02-01)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022-08-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2024-08-01)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
by: Yusuke Kunimatsu, et al.
Published: (2023-04-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
by: Takeshi Fukumoto, et al.
Published: (2022-08-01)

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
by: Rebecca Charles, et al.
Published: (2023-09-01)

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab
by: Shelby L Kubicki, et al.
Published: (2018-10-01)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
by: Lucía Vázquez-Montero, et al.
Published: (2023-06-01)

Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
by: M. A. Lyadova, et al.
Published: (2021-12-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden
by: Rebekka Mispelbaum, et al.
Published: (2024-06-01)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
by: Taku Fujimura, et al.
Published: (2018-01-01)

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
by: Brendan John Guercio, et al.
Published: (2021-03-01)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023-03-01)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
by: Bin Wu, et al.
Published: (2018-11-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
by: Irena Tan, et al.
Published: (2018-07-01)

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
by: Renata Pacholczak-Madej, et al.
Published: (2022-10-01)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
by: Jingjie Chen, et al.
Published: (2020-07-01)

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma
by: Ahmad A. Tarhini, et al.
Published: (2022-11-01)

Real‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer
by: Ayami Kaneko, et al.
Published: (2024-05-01)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
by: Huabin Hu, et al.
Published: (2020-09-01)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
by: Mikako Nakamura, et al.
Published: (2023-02-01)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
by: Liu Yang, et al.
Published: (2023-10-01)

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
by: Sheng IY, et al.
Published: (2020-06-01)

Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
by: Tomoki Taniguchi, et al.
Published: (2024-12-01)

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
by: Bowen Dai, et al.
Published: (2025-01-01)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022-07-01)

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
by: Hang Xu, et al.
Published: (2019-11-01)

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
by: Renata Pacholczak-Madej, et al.
Published: (2024-11-01)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
by: Ravi Potluri, et al.
Published: (2019-07-01)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
by: Katjana S. Schwab, et al.
Published: (2019-05-01)

Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
by: Aoi Motonaga, et al.
Published: (2021-09-01)

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial
by: Jeffrey M. Clarke, MD, et al.
Published: (2022-06-01)

External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma
by: Shuzo Hamamoto, et al.
Published: (2024-09-01)

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
by: Kazuyuki Numakura, et al.
Published: (2023-08-01)